Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors

PURPOSE: Anaplastic lymphoma kinase (ALK) rearrangement is a well-known driver oncogene in non–small-cell lung cancer and has also been identified in other types of tumors. However, there is limited evidence on the clinical response to ALK tyrosine kinase inhibitors (TKIs), such as alectinib and cri...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JCO Precis Oncol
Main Authors: Takeyasu, Yuki, Okuma, Hitomi S., Kojima, Yuki, Nishikawa, Tadaaki, Tanioka, Maki, Sudo, Kazuki, Shimoi, Tatsunori, Noguchi, Emi, Arakawa, Ayumu, Mori, Taisuke, Sunami, Kuniko, Kubo, Takashi, Kohno, Takashi, Akihiko, Yoshida, Yamamoto, Noboru, Yonemori, Kan
Formato: Artigo
Idioma:Inglês
Publicado: Wolters Kluwer Health 2021
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8140781/
https://ncbi.nlm.nih.gov/pubmed/34036223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.20.00383
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares